Acumen Pharmaceuticals (ABOS) Insider Porter Sells $30K of Stock
Derrell Porter sold 12,800 shares of ABOS for $29,824 on June 16, 2026.
Reviewed by automated data checks against the source filing. How we make and check alerts
Derrell Porter sold 12,800 shares of Acumen Pharmaceuticals, Inc. ($ABOS) at an average price of $2.33, worth about $29,824, on June 16, 2026. The trade was reported to the SEC in a Form 4 filing.
Since the trade, $ABOS is up 5.2% after 1 week, down 5.2% after 1 month and down 26.2% to date (from the $2.29 close on Jun 16, 2026).
ABOS
Acumen Pharmaceuticals, Inc.
Key Points
- Derrell Porter sold 12,800 ABOS shares at $2.33 each, totaling $29,824, on June 16, 2026.
- ABOS shares traded at $2.33, with strong institutional interest from RA Capital Management and others.
- Analysts from BTIG and B of A Securities maintain 'buy' ratings with price targets up to $11.
Get $ABOS trade alerts by text
We text you when insiders, Congress or big funds trade $ABOS. Free.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated Acumen Pharmaceuticals, Inc. alert may contain errors. Disclosures
On June 16, 2026, Derrell Porter sold 12,800 shares of ABOS at a price of $2.33 each, resulting in a total transaction value of $29,824. This sale was not part of a pre-planned trading program.
Other Institutional Activity in ABOS
RA Capital Management, L.P. significantly increased its stake in ABOS by adding 6,060,606 shares, bringing its total to 20,992,669 shares valued at approximately $49.5 million. Sands Capital Alternatives, LLC also boosted its holdings by 303,030 shares, ending with 3,720,105 shares worth about $8.8 million. Alyeska Investment Group, L.P. made a substantial addition of 1,515,151 shares, reaching a total of 2,454,754 shares valued at $5.8 million. Franklin Resources Inc and Knollwood Investment Advisory, LLC maintained their positions without any change.
Acumen Pharmaceuticals, Inc. Stock Down 12.1%
ABOS shares are trading at $2.33. The stock has seen active trading among institutional investors, with recent significant additions to holdings by major funds.
Insider Buying and Selling at Acumen Pharmaceuticals, Inc.
Derrell Porter has been active in trading ABOS shares, including a purchase of 13,040 shares at $1.07 on June 17, 2026, followed by a sale of the same number of shares at $2.33. Additionally, Porter sold 6,460 shares at $2.35 on June 15, 2026.
Analysts Set New Price Targets
On March 17, 2026, BTIG maintained its 'buy' rating for ABOS, setting a price target of $8. Earlier, on January 27, BTIG also maintained a 'buy' rating with a target of $7. B of A Securities has consistently maintained a 'buy' rating, with a target of $8 set on November 18, 2025. The consensus among analysts is a 'buy' recommendation, with an average target price reflecting optimism for the company's future performance.
About ABOS
ABOS operates in the biotechnology sector, focusing on innovative therapies. The company is committed to advancing its research and development efforts to bring new solutions to market. Headquartered in the U.S., ABOS aims to address unmet medical needs through its cutting-edge scientific approach.
Bottom Line
Derrell Porter's recent sale of ABOS shares highlights ongoing insider activity, with significant transactions occurring over a few days. Investors keep an eye on institutional movements and analyst ratings to gauge the stock's potential. Remember, insider transactions like these are reported after the fact and don't necessarily indicate current positions.
Related Filing Alerts
Source: Derrell Porter's Form 4 filing on $ABOS (Jun 16, 2026). Find the original filing: ABOS Form 4 filings on SEC EDGAR. Written by software, not financial advice. How we make alerts